Patient characteristics
Parameter . | Group 1 . | Group 2 . |
|---|---|---|
| No. male/no. female | 32/26 | 38/24 |
| Median age, y (range) | 51 (18-77) | 52 (18-71) |
| Cytogenetics | ||
| Favorable, no. (%) | 9 (16) | 14 (23) |
| Intermediate, no. (%) | 36 (62) | 35 (56) |
| Unfavorable, no. (%) | 13 (22) | 13 (21) |
| Median WBC count, g/L (range) | 14.4 (0.6-544.0) | 6.9 (0.9-223) |
| Allogeneic transplantation in CR1 | 16 | 14 |
| Median % bone marrow blasts on day 1 (range) | 80 (15-95) | 65 (15-100) |
| Median % LAIP-positive bone marrow cells on day 1 (range) | 18.81 (4.97-71.55) | 18.33 (4.97-73.22) |
| Median d of MRD assessment (range) | 75 (59-99) | 136 (101-168 |
| Median % LAIP-positive bone marrow cells at follow-up checkpoint (range) | 0.09 (0.00-2.25) | 0.08 (0.00-6.85) |
| Median LD at follow-up checkpoint (range) | 2.39 (0.51-3.56) | 2.29 (-0.07-4.26) |
| Median LAIP-positive cells in NBM (range) | 0.03 (0.00-0.64) | 0.07 (0.00-1.05) |
| Median log difference, day 1 to NBM (range) | 2.70 (1.05-4.23) | 2.53 (0.95-3.91) |
| Log difference, day 1 to NBM: less than 2 | 8 | 13 |
| Log difference, day 1 to NBM: 2 to 3 | 25 | 31 |
| Log difference, day 1 to NBM: more than 3 | 26 | 18 |
| Median maximum LAIP-positive cells in NBM, % (range) | 0.26 (0.00-5.21) | 0.48 (0.00-7.06) |
| Clinical follow-up, median mo | 10.0 | 13.5 |
| Overall survival at 2 y, % | 68 | 66 |
| Relapse-free survival at 2 y, % | 37 | 44 |
Parameter . | Group 1 . | Group 2 . |
|---|---|---|
| No. male/no. female | 32/26 | 38/24 |
| Median age, y (range) | 51 (18-77) | 52 (18-71) |
| Cytogenetics | ||
| Favorable, no. (%) | 9 (16) | 14 (23) |
| Intermediate, no. (%) | 36 (62) | 35 (56) |
| Unfavorable, no. (%) | 13 (22) | 13 (21) |
| Median WBC count, g/L (range) | 14.4 (0.6-544.0) | 6.9 (0.9-223) |
| Allogeneic transplantation in CR1 | 16 | 14 |
| Median % bone marrow blasts on day 1 (range) | 80 (15-95) | 65 (15-100) |
| Median % LAIP-positive bone marrow cells on day 1 (range) | 18.81 (4.97-71.55) | 18.33 (4.97-73.22) |
| Median d of MRD assessment (range) | 75 (59-99) | 136 (101-168 |
| Median % LAIP-positive bone marrow cells at follow-up checkpoint (range) | 0.09 (0.00-2.25) | 0.08 (0.00-6.85) |
| Median LD at follow-up checkpoint (range) | 2.39 (0.51-3.56) | 2.29 (-0.07-4.26) |
| Median LAIP-positive cells in NBM (range) | 0.03 (0.00-0.64) | 0.07 (0.00-1.05) |
| Median log difference, day 1 to NBM (range) | 2.70 (1.05-4.23) | 2.53 (0.95-3.91) |
| Log difference, day 1 to NBM: less than 2 | 8 | 13 |
| Log difference, day 1 to NBM: 2 to 3 | 25 | 31 |
| Log difference, day 1 to NBM: more than 3 | 26 | 18 |
| Median maximum LAIP-positive cells in NBM, % (range) | 0.26 (0.00-5.21) | 0.48 (0.00-7.06) |
| Clinical follow-up, median mo | 10.0 | 13.5 |
| Overall survival at 2 y, % | 68 | 66 |
| Relapse-free survival at 2 y, % | 37 | 44 |
LAIP indicates leukemia-associated aberrant immunophenotype; LD, log difference; NBM, normal bone marrow.